Lifetime Risks Temper Biomarker Tests for Alzheimer Dz Dementia
WEDNESDAY, June 6, 2018 -- The lifetime risks of Alzheimer's disease (AD) dementia vary considerably by age, gender, and the preclinical or clinical disease state, according to a study published online May 22 in Alzheimer's & Dementia.
Ron Brookmeyer, Ph.D., and Nada Abdalla, from the University of California in Los Angeles, used a multistate model for the disease process together with U.S. death rates to estimate the lifetime and 10-year risks of AD dementia.
The researchers found that there was considerable variation in lifetime risks of AD by age, gender, and the preclinical or clinical disease state of the individual. For a female with only amyloidosis, the lifetime risks were 8.4 and 29.3 percent for a 90- and 65-year-old, respectively. Lifetime risks of AD dementia greater than 50 percent were seen for persons younger than 85 years with mild cognitive impairment, amyloidosis, and neurodegeneration.
"Most persons with preclinical AD will not develop AD dementia during their lifetimes," the authors write. "Lifetime risks help interpret the clinical significance of biomarker screening tests for AD."
One author disclosed financial ties to Takeda.
© 2020 HealthDay. All rights reserved.
Posted: June 2018
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.